Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 62,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $10.38, for a total transaction of $645,636.00. Following the sale, the insider now directly owns 3,125,640 shares of the company’s stock, valued at approximately $32,444,143.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of CMPI stock opened at $10.39 on Friday. Checkmate Pharmaceuticals, Inc. has a 1 year low of $2.00 and a 1 year high of $10.45. The firm has a fifty day moving average price of $3.67 and a 200-day moving average price of $3.44. The company has a market cap of $224.75 million, a price-to-earnings ratio of -3.66 and a beta of 0.61.
Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last issued its quarterly earnings data on Tuesday, March 29th. The company reported ($0.62) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Checkmate Pharmaceuticals, Inc. will post -3.14 earnings per share for the current fiscal year.
A number of research firms have commented on CMPI. BTIG Research downgraded shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday. Zacks Investment Research raised shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday.
Checkmate Pharmaceuticals Company Profile (Get Rating)
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
- Get a free copy of the StockNews.com research report on Checkmate Pharmaceuticals (CMPI)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.